...Gareth S.A. Wright The efficacy of superoxide dismutase-1 (SOD1) folding impacts neuronal loss in motor system neurodegenerative diseases. Mutations can prevent SOD1 post-translational processing leading to misfolding and cytoplasmic aggregation in familial amyotrophic lateral sclerosis (ALS...

... with diacylglycerol (DAG) and PtdOH. Through these interactions, Nir2 functions in ER–PM contact zones. Mutations in VAP-B that have been identified in familial forms of amyotrophic lateral sclerosis (ALS or Lou-Gehrig's disease) cause aggregation of the VAP-B protein, which then impairs its binding to several...

...Laura Ferraiuolo Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder affecting the motor nerves. At present, there is no effective therapy for this devastating disease and only one Food and Drug Administration (FDA)-approved drug, riluzole, is known to moderately extend...

... Alzheimer’s disease amyotrophic lateral sclerosis glia Huntington’s disease neurodegeneration Parkinson’s disease Neuroglia, represented by highly heterogeneous population of non-excitable cells of ectodermal/neural (astroglia, oligodendroglia and NG-2 glia) and mesodermal/myeloid (microglia...

... address: Department of Physiology, The Royal College of Surgeons in Ireland, York House, York St., Dublin 2, Ireland. 2 To whom correspondence should be addressed (email l.greensmith@ion.ucl.ac.uk ). 22 3 2005 © 2005 The Biochemical Society 2005 amyotrophic lateral sclerosis...